BRAIN Biotech

BRAIN Biotech EBIT

The EBIT of BRAIN Biotech (BNN.DE) as of Nov 5, 2026 is -8.51 M EUR. In the previous year, EBIT was -8.85 M EUR — a change of -3.87% (higher).

EBIT

-8.51 MEUR

YoY

-3.87%

Last updated:

In 2025, BRAIN Biotech's EBIT was -8.51 M EUR, a -3.87% increase from the -8.85 M EUR EBIT recorded in the previous year.

The BRAIN Biotech EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-6.63 M EUR
Jan 1, 2024
-8.85 M EUR
Jan 1, 2025
-8.51 M EUR
Jan 1, 2026 (e)
-9.97 M EUR
Jan 1, 2027 (e)
-2.46 M EUR
Jan 1, 2028 (e)
-989,177.00 EUR
Jan 1, 2029 (e)
-1.36 M EUR
Jan 1, 2030 (e)
5.34 M EUR
The BRAIN Biotech EBIT history
YEAREBITYoY
est5.34 MEUR-492.65%
est-1.36 MEUR+37.56%
est-989,177.00EUR-59.84%
est-2.46 MEUR-75.29%
est-9.97 MEUR+17.16%
-8.51 MEUR-3.87%
-8.85 MEUR+33.49%
-6.63 MEUR-11.88%
-7.53 MEUR+14.92%
-6.55 MEUR-26.19%
-8.87 MEUR+56.98%
-5.65 MEUR-43.72%
-10.04 MEUR+10.09%
-9.12 MEUR-33.15%
-13.64 MEUR+198.37%
-4.57 MEUR-7.52%
-4.94 MEUR+12.66%
-4.39 MEUR-22.60%
-5.67 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BRAIN Biotech Revenue

BRAIN Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
55.34 M EUR
-6.63 M EUR
-8.28 M EUR
Jan 1, 2024
54.63 M EUR
-8.85 M EUR
-11.13 M EUR
Jan 1, 2025
49.62 M EUR
-8.51 M EUR
-11.74 M EUR
Jan 1, 2026 (e)
48.18 M EUR
-9.97 M EUR
-11.69 M EUR
Jan 1, 2027 (e)
53.67 M EUR
-2.46 M EUR
-4.17 M EUR
Jan 1, 2028 (e)
57.26 M EUR
-989,177.00 EUR
-2.69 M EUR
Jan 1, 2029 (e)
66.67 M EUR
-1.36 M EUR
-3.06 M EUR
Jan 1, 2030 (e)
74.91 M EUR
5.34 M EUR
2.88 M EUR

BRAIN Biotech Margins

BRAIN Biotech stock margins

The BRAIN Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BRAIN Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BRAIN Biotech.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
6.27 %
-11.98 %
-14.96 %
Jan 1, 2024
0.73 %
-16.20 %
-20.37 %
Jan 1, 2025
4.04 %
-17.15 %
-23.66 %
Jan 1, 2026 (e)
4.04 %
-20.69 %
-24.28 %
Jan 1, 2027 (e)
4.04 %
-4.59 %
-7.77 %
Jan 1, 2028 (e)
4.04 %
-1.73 %
-4.70 %
Jan 1, 2029 (e)
4.04 %
-2.04 %
-4.58 %
Jan 1, 2030 (e)
4.04 %
7.13 %
3.85 %

BRAIN Biotech Stock analysis

What does BRAIN Biotech do? The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing BRAIN Biotech's EBIT

BRAIN Biotech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of BRAIN Biotech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

BRAIN Biotech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in BRAIN Biotech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about BRAIN Biotech stock

EBIT of BRAIN Biotech is -8.51 M EUR in 2025.

EBIT of BRAIN Biotech changed from -8.85 M EUR to -8.51 M EUR, representing a -3.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT BRAIN Biotech since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's BRAIN Biotech historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BRAIN Biotech

All Key Metrics — BRAIN Biotech